Trials / Terminated
TerminatedNCT00537732
Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Matthias Schwab · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing (20 or 60mg/day) according how fast the patient can metabolize (eliminate) the drug. The individual elimination capacity is genetically controlled and therefore all patients will be genotyped prior to therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omeprazole | 20 mg daily |
| DRUG | omeprazole | 20 vs. 60 mg daily, genotype dependent |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2007-10-01
- Last updated
- 2014-02-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00537732. Inclusion in this directory is not an endorsement.